An Open-Label Study to Assess the Effect of CYP3A4 Induction on the Pharmacokinetics of VELCADE (Bortezomib).
Phase of Trial: Phase I
Latest Information Update: 27 Jan 2012
At a glance
- Drugs Bortezomib; Dexamethasone; Rifampicin
- Indications Multiple myeloma; Non-Hodgkin's lymphoma
- Focus Pharmacokinetics
- Sponsors Millennium
- 12 Jul 2011 Primary endpoint (Area under the drug concentration time curve) added as reported by ClinicalTrials.gov.
- 19 Jul 2010 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 19 Feb 2010 Planned end date changed from Dec 2009 to Apr 2010 as reported by ClinicalTrials.gov.